Biogen (BIIB) said Thursday that the US Food and Drug Administration has granted breakthrough therapy designation for Salanersen to treat spinal muscular atrophy, a rare, genetic and neuromuscular disease.
The designation is intended to expedite the development and review of drugs that treat a serious condition.
The biotech firm said preliminary clinical evidence suggests the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments